CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Respiratorius AB (publ) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Respiratorius AB (publ)
Medicon Village, Scheeletorget 1
Phone: +46 709224140p:+46 709224140 LUND, 223 81  Sweden Ticker: RESPRESP
Business Summary
Respiratorius AB (publ) is a Sweden-based biotechnology and pharmaceutical company. It develops candidate drugs for treatment of cancer, Chronic Obstructive Pulmonary Disease (COPD) and asthma. The project portfolio also includes development of a biomarker for cardiovascular positron-emission tomography (PET)-imaging. The oncology drug project VAL-001 aims for first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL). In the COPD and asthma projects, the Company develops two classes of drug substances, such as RESP-1000 and RESP-2000 series for bronchodilating effect on small airways. The Company’s primary markets are the United States and South Africa.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board KarinWehlin 5/16/2023 5/16/2023
Chief Executive Officer, Director JohanDrott 5/16/2023 5/16/2023
Director - Chemistry, Manufacturing, and Control Carl-MagnusAndersson 11/26/2020 11/26/2020
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 509,854,897 (As of 9/30/2024)
Stock Exchange: AKT


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024